The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
Open accessAbstract
UNLABELLED: We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a low-molecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA). PSMA has been shown to be associated with higher Gleason grade and more aggressive disease. An imaging biomarker able to detect clinically significant high-grade primary prostate cancer reliably would address an unmet clinical need by allowing for risk-adapted patient management. METHODS: We enrolled 13 patients with primary prostate cancer who were imaged with (18)F-DCFBC PET before scheduled prostatectomy, with 12 of these patients also undergoing pelvic prostate MR imaging. Prostate (18)F-DCFBC PET was correlated with MR imaging and histologic and immunohistochemical analysis on a prostate-segment (12 regions) and dominant-lesion basis. There were no incidental extraprostatic findings on PET suggestive of metastatic disease. RESULTS: MR imaging was more sensitive than (18)F-DCFBC PET for detection of primary prostate cancer on a per-segment (sensitivities of up to 0.17 and 0.39 for PET and MR imaging, respectively) and per-dominant-lesion analysis (sensitivities of 0.46 and 0.92 for PET and MR imaging, respectively). However, (18)F-DCFBC PET was more specific than MR imaging by per-segment analysis (specificities of 0.96 and 0.89 for PET and MR imaging for corresponding sensitivity, respectively) and specific for detection of high-grade lesions (Gleason 8 and 9) greater than 1.0 mL in size (4/4 of these patients positive by PET). (18)F-DCFBC uptake in tumors was positively correlated with Gleason score (ρ = 0.64; PSMA expression, ρ = 0.47; and prostate-specific antigen, ρ = 0.52). There was significantly lower (18)F-DCFBC uptake in benign prostatic hypertrophy than primary tumors (median maximum standardized uptake value, 2.2 vs. 3.5; P = 0.004). CONCLUSION: Although the sensitivity of (18)F-DCFBC for primary prostate cancer was less than MR imaging, (18)F-DCFBC PET was able to detect the more clinically significant high-grade and larger-volume tumors (Gleason score 8 and 9) with higher specificity than MR imaging. In particular, there was relatively low (18)F-DCFBC PET uptake in benign prostatic hypertrophy lesions, compared with cancer in the prostate, which may allow for more specific detection of primary prostate cancer by (18)F-DCFBC PET. This study demonstrates the utility of PSMA-based PET, which may be used in conjunction with MR imaging to identify clinically significant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Cited by
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Afshar-Oromieh, A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Mier, W., Haufe, S., Debus, N., Eder, M., Eisenhut, M., Schäfer, M., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3711-7 · Cited by 507
Sheikhbahaei, S., Afshar-Oromieh, A., Eiber, M., Solnes, L. B., Javadi, M. S., Ross, A. E., Pienta, K. J., Allaf, M. E., Haberkorn, U., Pomper, M. G., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3780-7 · Cited by 295
Self-citationRowe, S. P., Macura, K. J., Mena, E., Blackford, A. L., Nadal, R., Antonarakis, E. S., Eisenberger, M., Carducci, M., Fan, H., Dannals, R. F., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0957-6 · Cited by 258
Self-citationGarland, M., Yim, J. J., & Bogyo, M. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2015.12.003 · Cited by 254
Metadata
- Authors
- Rowe, S. P., Gage, K. L., Faraj, S. F., Macura, K. J., Cornish, T. C., Gonzalez-Roibon, N., Guner, G., Munari, E., Partin, A. W., Pavlovich, C. P., Han, M., Carter, H. B., Bivalacqua, T. J., Blackford, A., Holt, D., Dannals, R. F., Netto, G. J., Lodge, M. A., Mease, R. C., Pomper, M. G., & Cho, S. Y.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2015-06-11
- Volume
- 56
- Issue
- 7
- Pages
- 1003-1010
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W1919117211
- Cited by
- 196
- References
- 1
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. https://app.cochat.ai/papers/10.2967/jnumed.115.154336
- The paper
- Rowe, S. P., Gage, K. L., Faraj, S. F., Macura, K. J., Cornish, T. C., Gonzalez-Roibon, N., Guner, G., Munari, E., Partin, A. W., Pavlovich, C. P., Han, M., Carter, H. B., Bivalacqua, T. J., Blackford, A., Holt, D., Dannals, R. F., Netto, G. J., Lodge, M. A., Mease, R. C., . . . Cho, S. Y. (2015). 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.115.154336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.